Cover Image
Market Research Report
Product code 
1065215

Global Hypereosinophilic Syndrome Market - 2022-2029

Published: | DataM Intelligence | 180 Pages | Delivery time: 2 business days

Price

Back to Top
Global Hypereosinophilic Syndrome Market - 2022-2029
Published: May 7, 2022
DataM Intelligence
Content info: 180 Pages
Delivery time: 2 business days
  • Description
  • Table of Contents

Market Overview

The global hypereosinophilic syndrome market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Hypereosinophilic syndrome (HES) is characterized by an abnormally high eosinophil count in the blood. Eosinophils are white blood cells that play an important role in the immune system. An increased eosinophil count usually indicates an infection or an allergic reaction in the body. Hypereosinophilic syndrome is a rare blood disorder characterized by persistent eosinophilia and higher eosinophil counts than normal. For more than six months in patients with hypereosinophilic syndrome, the blood eosinophil count is greater than 1500/ml. This condition's cause is unknown. The continuous presence of high eosinophil counts is linked to various clinical manifestations, including organ tissue inflammation and, eventually, organ damage.

Market Dynamics

The hypereosinophilic syndrome market is expected to grow due to increased awareness of the condition, increased investment by major players globally, increased government initiatives, and a robust product pipeline. Furthermore, the rising prevalence of various health conditions that result in hypereosinophilic syndromes, such as autoimmune disorders, endocrine disorders, and adrenal disorders, is expected to drive the hypereosinophilic syndrome market.

The increase in prevalance of autoimmune disorders in the market will drive the market growth

The market for hypereosinophilic syndrome is being pushed by an increase in autoimmune disorders,endocrine disorders and adrenal disorders. The Autoimmune Related Diseases Association estimates that up to 50 million Americans suffer from an autoimmune disease at the cost of $86 billion per year. According to the United States Department of Health and Human Services, these diseases are the fourth leading cause of disability amid women in the United States and the eighth leading cause of death amid women aged 15 to 64.

Adrenal disorders affect approximately 100 to 140 people out of every million in developed countries.Secondary adrenal insufficiency is more prevalent, affecting 150 to 280 people per million people.(Source-National Institutes of Health).

Evidence suggests that the global burden of endocrine disorders is increasing due to an aging population, obesity, poor lifestyle and dietary habits. Endocrine disorders affect about 5% of the population in the United States.The exact prevalence of endocrine disorders in Indians is unknown. Thyroid disorders and diabetes are the most common endocrine disorders in India.Diabetes affects 11.8 percent of the Indian population, accounting for 72.96 million adult cases. In India's adult population, the overall prevalence of hypothyroidism is around 10.9 percent.

Furthermore, the burden of blood-borne diseases has increased in recent years, along with the rising prevalence of geriatric population, raising public awareness about treatment available, and several government initiatives related to hypereosinophilic syndrome , all of which are driving the overall market.This contributes to the growth of the global hypereosinophilic syndrome market.

Lack of awareness about hypereosinophilic syndrome is likely to hamper the market growth

The lack of awareness of hypereosinophilic syndrome in emerging regions and the high cost of treatment and poor health care infrastructure in developing nations is expected to limit the hypereosinophilic syndrome market over the projection period.

COVID-19 Impact Analysis

Over the projection period, the increased prevalence of COVID-19 is expected to impact hypereosinophilic syndrome market growth. The majority of pharmaceutical businesses have suffered considerable losses due to the coronavirus outbreak, which has hampered the hypereosinophilic syndrome market. The COVID-19 pandemic has had a remarkable influence on the global economy; this has significantly impacted production processes and demand across multiple verticals and disrupted the supply chain. During the initial phase of the COVID, many businesses ceased manufacturing and supply operations. However, the current COVID-19 situation is expected to return to normalcy as medical professionals and health authorities in the countries take the necessary steps to combat the virus. Furthermore, pharmaceutical companies and research institutions worldwide have focused their efforts on developing a vaccine for COVID-19, putting the development of other therapeutics on hold.

Segment Analysis

The injectables segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Over the projection period, the injectables segment is expected to increase . The rising number of autoimmune disorders, the rising number of hypereosinophilic syndrome cases, and the rising frequency of chronic disease-induced diabetes and cancer contribute to the segment's rise. For example, According to WHO, Cancer is the largest cause of death in the world, with approximately 10 million fatalities expected by 2020.

Furthermore, benralizumab as the first line of eosinophilia treatment.Major key players Like GlaxoSmithKline,Bristol-Myers Squibb are also doing R&D in this segment so these factors play a key role in development of this segment.

Geographical Analysis

North America region holds the largest market share of global hypereosinophilic syndrome market

North America ruled the global market in 2021 due to the high prevalence of autoimmune disorders, the rise in cancer prevalence, and widespread awareness of various blood disorders. According to the America Autoimmune Related Disease Association (AARDA), approximately 50 million Americans were diagnosed with autoimmune disorders in 2017, and their prevalence is still on the rise. According to the American Cancer Society statistics 2018, approximately 1,735,350 new cancer cases will be diagnosed in 2018, with 609,640 cancer deaths expected in the United States.Furthermore, the presence of many key players in North America is a major factor driving market growth.

However, Asia-Pacific is assessed to grow the fastest during the forecast period, due to increased awareness, increased health-care spending, and technological advancements which contribute to the growth of the Asia-Pacific hypereosinophilic syndrome market.

Competitive Landscape

The hypereosinophilic syndrome market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include GlaxoSmith Kline plc, Bristol-Myers Squibb Company,Kyowa Hakko Kirin Co.Ltd, Knopp Biosciences LLC, Stemline Therapeutics Inc, F.Hoffmann-La Roche Ltd, Novartis AG.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the blood and blood products market globally. For instance in 2019, Knopp Biosciences has formed a partnership with leading UK researchers to begin a Phase 2 clinical trial of dexpramipexole in patients with severe eosinophilic asthma.

GlaxoSmithKline plc

Overview: GlaxoSmithKline (GSK) is a pharmaceutical company that develops, manufactures, and markets human health products. Analgesic, anti-infective, cardiovascular, anti-inflammatory, diabetes, anti-parasitic, dermatology, endocrine, gastrointestinal, gynecology, immune suppressants, nutritional, respiratory, central nervous system (CNS), and oncology are among the therapeutic areas covered by prescription medications. The company provides vaccines to prevent hepatitis A, hepatitis B, influenza, diphtheria, tetanus, pertussis, rotavirus, tetanus toxoid, reduced diphtheria toxoid, human papillomavirus vaccine, and other diseases.

Product Portfolio:

Nucala: Mepolizumab (Nucala) is a humanized monoclonal antibody used to treat severe eosinophilic asthma, eosinophilic granulomatosis, and hypereosinophilic syndrome (HES). It recognizes and inhibits interleukin-5 (IL-5), an immune system signaling protein.

Why Purchase the Report?

Visualize the composition of the global hypereosinophilic syndrome market segmentation by drug type, route of administration, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in global hypereosinophilic syndrome market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global hypereosinophilic syndrome market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global hypereosinophilic syndrome market report would provide an access to an approximately 40+ market data table, 45+ figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Hypereosinophilic Syndrome Market- By Drug Type

Benralizumab

Dasatinib

Dexpramipexole Dihydrochloride

Mepolizumab

Others

Global Hypereosinophilic Syndrome Market- By Route of Administration

Oral

Injectables

Global Hypereosinophilic Syndrome Market- By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Global Hypereosinophilic Syndrome Market- By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America

Product Code: DMPH4864

Table of Contents

1. Global Hypereosinophilic Syndrome Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Hypereosinophilic Syndrome Market- Market Definition and Overview

3. Global Hypereosinophilic Syndrome Market- Executive Summary

  • 3.1. Market Snippet by Drug Type
  • 3.2. Market snippet by Route of Administration
  • 3.3. Market snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Hypereosinophilic Syndrome Market- Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers.
      • 4.1.1.1. Rise in prevalence of autoimmune disorders, endocrine disorders across the globe.
      • 4.1.1.2. Technological advancement
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness about hypereosinophilic syndrome
      • 4.1.2.2. Poor healthcare infrastructure
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Hypereosinophilic Syndrome Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis

6. Global Hypereosinophilic Syndrome Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Hypereosinophilic Syndrome Market- By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
    • 7.1.2. Market Attractiveness Index, By Drug Type Segment
  • 7.2. Benralizumab*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Dasatinib
  • 7.4. Dexpramipexole Dihydrochloride
  • 7.5. Mepolizumab
  • 7.6. Others

8. Global Hypereosinophilic Syndrome Market- By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Injectable

9. Global Hypereosinophilic Syndrome Market- By Distribution Channel

  • 9.1 Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies
  • 9.5. Others

10. Global Hypereosinophilic Syndrome Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis ,and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Route of Administration
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Hypereosinophilic Syndrome Market- Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. Key Companies to Watch

12. Global Hypereosinophilic Syndrome Market- Company Profiles

  • 12.1. GlaxoSmithKline plc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Novartis AG
  • 12.3. Bristol-Myers Squibb Company
  • 12.4. Kyowa Hakko Kirin CoLtd
  • 12.5. Knopp Biosciences LLC
  • 12.6. Stemline Therapeutics Inc
  • 12.7. F.Hoffmann-La Roche Ltd

LIST NOT EXHAUSTIVE

13. Global Hypereosinophilic Syndrome Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us